Starting HRT in Perimenopause: Doses, Titration and What to Expect
A practical guide to starting doses for common HRT preparations in perimenopause, how titration works, and what to expect in the first 12 weeks.
Why Starting Low and Going Slow Matters
Starting HRT at the lowest effective dose and adjusting upward as needed is the approach recommended by NICE and supported by most menopause specialists. This strategy serves two purposes: it minimises side effects during the adjustment phase, and it establishes the minimum dose that controls symptoms, reducing unnecessary hormone exposure. During perimenopause, hormone levels fluctuate considerably from day to day and month to month. This means a dose that feels too low one week may feel adequate the next as endogenous production varies. It takes time for the body to reach a stable state on any new HRT preparation, and it takes time for symptoms to respond. Women who increase their dose too quickly based on symptoms in the first two to four weeks often overshoot what they actually need and end up managing dose-related side effects. Starting low, waiting at least six to eight weeks before evaluating efficacy, and making one change at a time allows for a much more accurate assessment of what the body needs. The first three months are a calibration period, not a definitive reading of whether HRT will work.
Starting Doses for Common Oestrogen Preparations
The most commonly prescribed oestrogen preparations in the UK and their typical starting doses reflect the range of available formulations. Oestrogel (oestradiol gel) is usually started at one pump daily (0.75 mg oestradiol), applied to the inner arm or thigh and rotated between sites. Two pumps (1.5 mg) is often needed for adequate symptom control and is a common maintenance dose. Sandrena sachets come in 0.5 mg and 1 mg strengths, with 0.5 mg being the typical starting point. Patches such as Evorel and Estradot come in strengths ranging from 25 mcg to 100 mcg delivered per 24 hours; 25 mcg or 50 mcg are typical starting doses. Oestrogen sprays such as Lenzetto deliver 1.53 mg per spray and are usually started at one spray daily. Oral oestradiol tablets (1 mg or 2 mg) are less commonly started now given the preference for transdermal routes, but 1 mg is the typical starting dose. All of these doses may need upward adjustment after six to eight weeks if symptom control is inadequate. Dose increases should be made one step at a time with a review period in between.
Starting the Progestogen Component
Women who have a uterus must take a progestogen alongside oestrogen to protect the uterine lining from the proliferative effects of unopposed oestrogen. The timing and type of progestogen depend on the formulation chosen. Micronised progesterone (Utrogestan) is commonly used in the UK and is taken either continuously at 100 mg daily (for continuous combined HRT in post-menopausal women) or cyclically at 200 mg for 12 days per month (for sequential HRT in perimenopausal women). Sequential progestogen is the standard starting approach for women who are still having periods or have had a period within the last 12 months, as it mimics a more natural hormonal pattern and causes a predictable monthly withdrawal bleed. Synthetic progestogens such as norethisterone or levonorgestrel come in lower doses and are found in combination patches or prescribed separately. The Mirena coil delivers levonorgestrel directly into the uterus and provides progestogen cover for HRT without systemic progestogen tablets. The dose considerations for the progestogen component are somewhat simpler than for oestrogen: the primary goal is endometrial protection, and standard doses achieve this reliably.
What to Expect in the First Four Weeks
The first month on HRT is often one of adjustment rather than clear improvement. Some women feel noticeably better within one to two weeks, particularly for symptoms like sleep disruption and mood instability. Others notice little change at first, which does not mean HRT is failing. Hot flashes may reduce in frequency but not disappear entirely. Energy levels may feel slightly more stable. Mood might feel less volatile. Alongside these small improvements, common side effects often appear in the first four weeks: mild breast tenderness, some bloating, occasional headaches if using an oral preparation, or irregular spotting if using combined HRT. These are expected responses to hormonal adjustment. It is not advisable to make dose changes in the first four weeks unless side effects are severe, as the system needs time to reach a baseline. Keeping a simple daily log of symptoms and side effects using a notes app or dedicated menopause diary helps enormously when the four to six week review appointment comes around. This evidence-based conversation with your prescriber allows for meaningful adjustments rather than guesswork.
Titrating the Dose at Six to Twelve Weeks
The six to eight week mark is the point at which a meaningful assessment of symptom control becomes possible. If hot flashes, night sweats, sleep disruption, or mood symptoms are still significantly impacting quality of life at this point, an increase in oestrogen dose is typically the next step. For gel or spray users, this means adding another pump or spray. For patch users, moving to the next strength up. For women on oral oestradiol, increasing from 1 mg to 2 mg. The prescriber will also assess whether the progestogen component is causing problems. If bleeding is irregular, if mood deteriorates noticeably during the progestogen phase, or if bloating is prominent in the second half of the cycle, the progestogen type or timing may need adjustment. By 12 weeks, most women should have a clearer sense of whether their current regimen is working and whether any modifications are needed. A second review around 12 weeks is standard good practice. The goal is adequate symptom control with the fewest side effects, not the highest possible dose. Some women need relatively low doses; others need higher doses to feel well. Both outcomes are valid.
When Dose Adjustments Are Not Enough
Occasionally, straightforward dose adjustments do not resolve the combination of persistent symptoms and troublesome side effects, and a more significant change is needed. This might mean switching the route of administration entirely, for example from patches to gel if skin reactions are an issue, or from gel to patches if absorption is inconsistent. It might mean switching the progestogen, from Utrogestan tablets to the Mirena coil, for women who experience notable progestogen intolerance. Some women find they need higher oestrogen doses than standard preparations allow, and a menopause specialist can prescribe compounded or higher-strength preparations in these cases. Women in early perimenopause may find their symptoms fluctuate more dramatically than those in later perimenopause because endogenous oestrogen is still being produced erratically. For these women, adjusting the route or using a preparation that allows more flexible dosing can be helpful. If after six months a woman still feels that her symptoms are poorly controlled or side effects are unmanageable, referral to a specialist menopause clinic is appropriate. The British Menopause Society maintains a directory of accredited menopause specialists.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.